PeterLabs Holdings Berhad Past Earnings Performance
Past criteria checks 1/6
PeterLabs Holdings Berhad's earnings have been declining at an average annual rate of -1.2%, while the Pharmaceuticals industry saw earnings growing at 8.9% annually. Revenues have been growing at an average rate of 17.6% per year. PeterLabs Holdings Berhad's return on equity is 5%, and it has net margins of 1.9%.
Key information
-1.2%
Earnings growth rate
-7.7%
EPS growth rate
Pharmaceuticals Industry Growth | 7.7% |
Revenue growth rate | 17.6% |
Return on equity | 5.0% |
Net Margin | 1.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
PeterLabs Holdings Berhad (KLSE:PLABS) Seems To Use Debt Quite Sensibly
Nov 10Is PeterLabs Holdings Berhad (KLSE:PLABS) A Risky Investment?
Jan 28With EPS Growth And More, PeterLabs Holdings Berhad (KLSE:PLABS) Makes An Interesting Case
Nov 10Is Now The Time To Put PeterLabs Holdings Berhad (KLSE:PLABS) On Your Watchlist?
Feb 02Are PeterLabs Holdings Berhad's (KLSE:PLABS) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Dec 28Are PeterLabs Holdings Berhad's (KLSE:PLABS) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 30Revenue & Expenses BreakdownBeta
How PeterLabs Holdings Berhad makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 186 | 3 | 18 | 0 |
30 Sep 23 | 181 | 3 | 18 | 0 |
30 Jun 23 | 173 | 3 | 17 | 0 |
31 Mar 23 | 169 | 3 | 17 | 0 |
31 Dec 22 | 162 | 4 | 16 | 0 |
30 Sep 22 | 163 | 5 | 16 | 0 |
30 Jun 22 | 171 | 5 | 16 | 0 |
31 Mar 22 | 176 | 5 | 17 | 0 |
31 Dec 21 | 184 | 5 | 18 | 0 |
30 Sep 21 | 161 | 5 | 16 | 0 |
30 Jun 21 | 134 | 4 | 16 | 0 |
31 Mar 21 | 107 | 4 | 14 | 0 |
31 Dec 20 | 80 | 4 | 12 | 0 |
30 Sep 20 | 85 | 4 | 12 | 0 |
30 Jun 20 | 90 | 4 | 12 | 0 |
31 Mar 20 | 95 | 4 | 13 | 0 |
31 Dec 19 | 96 | 4 | 12 | 0 |
30 Sep 19 | 96 | 4 | 12 | 0 |
30 Jun 19 | 94 | 4 | 11 | 0 |
31 Mar 19 | 92 | 4 | 11 | 0 |
31 Dec 18 | 90 | 4 | 12 | 0 |
30 Sep 18 | 88 | 4 | 12 | 0 |
30 Jun 18 | 93 | 4 | 12 | 0 |
31 Mar 18 | 93 | 4 | 12 | 0 |
31 Dec 17 | 95 | 4 | 12 | 0 |
30 Sep 17 | 96 | 3 | 12 | 0 |
30 Jun 17 | 90 | 4 | 12 | 0 |
31 Mar 17 | 87 | 4 | 12 | 0 |
31 Dec 16 | 84 | 3 | 12 | 0 |
30 Sep 16 | 80 | 3 | 11 | 0 |
30 Jun 16 | 80 | 4 | 11 | 0 |
31 Mar 16 | 77 | 3 | 10 | 0 |
31 Dec 15 | 73 | 3 | 10 | 0 |
30 Sep 15 | 70 | 4 | 10 | 0 |
30 Jun 15 | 63 | 3 | 9 | 0 |
31 Mar 15 | 61 | 3 | 9 | 0 |
31 Dec 14 | 55 | 3 | 8 | 0 |
30 Sep 14 | 52 | 2 | 8 | 0 |
30 Jun 14 | 51 | 2 | 8 | 0 |
31 Mar 14 | 50 | 2 | 8 | 0 |
31 Dec 13 | 50 | 2 | 7 | 0 |
30 Sep 13 | 50 | 2 | 8 | 0 |
30 Jun 13 | 48 | 3 | 8 | 0 |
Quality Earnings: PLABS has high quality earnings.
Growing Profit Margin: PLABS's current net profit margins (1.9%) are lower than last year (2.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PLABS's earnings have declined by 1.2% per year over the past 5 years.
Accelerating Growth: PLABS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PLABS had negative earnings growth (-4.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-4.8%).
Return on Equity
High ROE: PLABS's Return on Equity (5%) is considered low.